Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Beyond nausea, Zepbound (tirzepatide) can cause surprising effects like sulfur burps, hiccups, altered taste or smell, body odor changes, hair thinning, fatigue, dizziness, and injection-site reactions. Many of these ease within a few weeks as your body adapts or after a dose stays steady, while others, such as persistent vomiting, severe abdominal pain, or vision changes, signal something that needs prompt attention. Which ones fade and which ones linger depends on your dose timing, hydration, eating patterns, and other medications, so the details below matter before you decide to push through or pause.
Because "normal adjustment" and "warning sign" can look nearly identical in the first weeks, guessing is the riskiest option. Take a free, instant, online symptom check to see how your specific symptoms line up and what reasonable next steps look like.
Last reviewed for medical accuracy: 10/22/2026
Zepbound (tirzepatide) is an injectable prescription medication originally approved for type 2 diabetes and more recently for weight management. Like any drug, it carries common side effects—nausea, diarrhea, constipation, headache—but there are also some less expected, “weird” side effects you may not read about as often. Below, we cover these unusual reactions, how long they tend to stick around, and when it’s time to talk to a doctor.
A “weird” side effect is one that’s less common or not frequently discussed in patient guides. Even if it affects a small percentage of users, knowing about these reactions helps you:
Metallic or Altered Taste
Hair Thinning or Shedding
Dizziness or Lightheadedness
Unexpected Skin Reactions
Blurry Vision or Eye Discomfort
Gallbladder or Biliary Issues
Mood Changes or Irritability
New-Onset Fatigue or Weird Energy Swings
Sweating Changes
Tingling or Numbness
Most weird side effects of Zepbound improve as your body adjusts. Here’s a general timeline:
First 4–8 weeks
• Gastrointestinal ups and downs (even “weird” taste changes) often settle.
• Dizziness and unusual fatigue usually improve as your hydration and diet stabilize.
8–12 weeks
• Mild skin reactions and injection-site redness typically disappear.
• Mood swings often level out once blood sugar and hunger hormones balance.
3–6 months
• Hair shedding from rapid weight loss may peak then gradually stop.
• Temperature regulation (sweating changes) often normalizes.
Beyond 6 months
• Gallstones or biliary sludge can still appear, especially if weight loss remains rapid.
• Any lingering vision issues should prompt an eye exam.
Keep in mind individual timelines vary. If you’re still noticing a strange symptom after 3 months, it’s worth tracking and discussing with your healthcare provider.
If you’re unsure whether a symptom is serious, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Some side effects demand prompt medical attention:
For life-threatening or serious symptoms, call emergency services or go to the nearest emergency department. For anything worrying but not urgent, schedule an appointment with your doctor—don’t wait.
Zepbound can offer significant benefits for blood sugar control and weight management, but it’s not without quirks. Knowing about the weird side effects of Zepbound—and understanding which ones fade—helps you:
Always keep an open line with your doctor. If you notice anything unexpected—good or bad—bring it up. Your well-being depends on both you and your healthcare provider staying in sync.
Speak to a doctor about any serious or life-threatening concerns you may have.
(References)
* Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J, SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21. PMID: 38912654; PMCID: PMC11598664.
* Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
* Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA, SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945. PMID: 38078870; PMCID: PMC10714284.
* Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA, SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16. PMID: 39555826.
* Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PMID: 40353578.
* Brož J, Koželuhová M, Michalec J, Lukáč O. Tirzepatide. Ceska Slov Farm. 2026;75(2):112-116. doi: 10.36290/csf.2026.020. PMID: 42334912.
* Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I, SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13. PMID: 39536238.
* Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):551-560. doi: 10.1001/jama.2024.9217. PMID: 38819983; PMCID: PMC11337071.
* Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, Gomez-Valderas E, Arad AD, Das S, Dunn JP, Ribeiro A, Glass LC, Lee CJ. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026 Jun 6;407(10545):2305-2318. doi: 10.1016/S0140-6736(26)00656-2. Epub 2026 May 12. PMID: 42119587.
* Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. PMID: 34186022.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.